ALR · Alerislife Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $286.58M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $17.02M | $17.84M | $18.19M | - | $21.82M | $22.75M | $22.64M | - | $19.92M | $23.57M |
| Total Operating Expenses | $189.96M | $177.76M | $181.49M | - | $232.52M | $270.93M | $273.23M | - | $291.63M | $285.24M |
| D&A | $3.09M | $3.28M | $3.16M | - | $2.98M | $2.99M | $2.94M | - | $2.68M | $2.70M |
| Operating Income | ($7.30M) | ($6.64M) | ($8.30M) | - | ($6.69M) | ($12.31M) | $3.66M | - | $3.69M | $1.34M |
| Interest Expense | $1.47M | $1.25M | $1.03M | - | $507.0K | $409.0K | $463.0K | - | $379.0K | $409.0K |
| Income Tax | $31.0K | ($9.0K) | $77.0K | - | ($164.0K) | $158.0K | $200.0K | - | $465.0K | ($902.0K) |
| Net Income | ($8.51M) | ($8.80M) | ($9.73M) | - | ($10.20M) | ($12.30M) | $3.31M | - | $3.71M | $3.00M |
| EPS - Basic | ($0.27) | ($0.28) | ($0.31) | - | ($0.32) | ($0.39) | ($0.55) | - | $0.12 | $0.10 |
| EPS - Diluted | ($0.27) | ($0.28) | ($0.31) | - | ($0.32) | ($0.39) | ($0.55) | - | ($1.41) | $0.10 |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $79.13M | $83.46M | $88.05M | $66.99M | $80.19M | $99.27M | $109.48M | $84.35M | $95.78M | $76.11M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $16.37M | $14.97M | $11.87M | $37.52M | $16.44M | $21.83M | $23.45M | - | $21.54M | $15.57M |
| Current Assets | $199.32M | $205.10M | $211.63M | $186.83M | $185.15M | $252.54M | $270.87M | $262.31M | $250.65M | $223.68M |
| Total Assets | $382.54M | $390.01M | $396.47M | $376.28M | $370.44M | $451.68M | $471.13M | $454.21M | $444.31M | $417.11M |
| Current Liabilities | $126.13M | $121.35M | $114.85M | $140.91M | $122.37M | $174.10M | $179.07M | $177.91M | $171.91M | $145.49M |
| Long-term Debt | $67.16M | $67.07M | $6.36M | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $154.33M | $163.01M | $171.54M | $181.59M | $191.77M | $201.97M | $213.63M | $210.53M | $207.56M | $204.11M |
| Retained Earnings | ($308.11M) | ($299.60M) | ($290.79M) | ($281.06M) | ($270.33M) | ($260.13M) | ($247.82M) | ($251.14M) | ($253.98M) | ($257.70M) |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($33.07M) | - | - | - | $26.83M | - | - | - |
| Investing Cash Flow | - | - | ($5.74M) | - | - | - | ($1.93M) | - | - | - |
| Financing Cash Flow | - | - | $60.04M | - | - | - | ($103.0K) | - | - | - |
| CapEx | - | - | $6.40M | - | - | - | $2.14M | - | - | - |
| Free Cash Flow | - | - | ($39.47M) | - | - | - | $24.69M | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | 0.5% |
| EBITDA margin | - | - | - | - | - | - | - | - | - | 1.4% |
| Net margin | - | - | - | - | - | - | - | - | - | 1.0% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 4.06 | - | - | - | 7.45 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | 8.2% |
| Effective tax rate | - | - | - | - | - | - | 5.7% | - | 11.1% | -43.0% |
| Return on assets | -2.2% | -2.3% | -2.5% | - | -2.8% | -2.7% | 0.7% | - | 0.8% | 0.7% |
| Return on equity | -5.5% | -5.4% | -5.7% | - | -5.3% | -6.1% | 1.6% | - | 1.8% | 1.5% |
| Return on invested capital | -2.6% | -2.3% | -3.7% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.58 | 1.69 | 1.84 | 1.33 | 1.51 | 1.45 | 1.51 | 1.47 | 1.46 | 1.54 |
| Quick ratio | 1.58 | 1.69 | 1.84 | 1.33 | 1.51 | 1.45 | 1.51 | 1.47 | 1.46 | 1.54 |
| Cash ratio | 0.63 | 0.69 | 0.77 | 0.48 | 0.66 | 0.57 | 0.61 | 0.47 | 0.56 | 0.52 |
| Leverage | ||||||||||
| Debt / Equity | 0.44 | 0.41 | 0.04 | - | - | - | - | - | - | - |
| Debt / Assets | 0.18 | 0.17 | 0.02 | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5.0x | -5.3x | -8.0x | - | -13.2x | -30.1x | 7.9x | - | 9.7x | 3.3x |
| Equity multiplier | 2.48 | 2.39 | 2.31 | 2.07 | 1.93 | 2.24 | 2.21 | 2.16 | 2.14 | 2.04 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | 0.69 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | -19.4% |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | -6.4% |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | -3.5% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -9.2% | 46.0% | - | - | - | - | -57.5% | - | - | -64.0% |
| Net income growth (YoY) | 16.6% | 28.4% | - | - | - | - | - | - | - | -28.2% |
| EPS growth (YoY) | 15.6% | 28.2% | 43.6% | - | 77.3% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | 614.8% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -19.5% | -19.3% | -19.7% | -13.7% | -7.6% | -1.0% | 6.5% | 75.5% | 100.0% | 86.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$43.46M totalManagement Fees$43.46M · 100.0%
Peer comparison
Same SIC group: Services-Skilled Nursing Care Facilities
Comparing AlerisLife Inc. against the 3 most active filers in the same SIC group.